United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 4

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Revenue Cohort 4 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderIovance · 50

Strongest available pathMonte Rosa Therapeutics · -59.9%

Widest latest marginMonte Rosa Therapeutics · -31.2%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1IOVA · Nasdaq

Iovance

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Carlos, California$3.63B market cap

View full Companies Radar profile

50Moderate

Snapshot price$8.01as of page date

Monthly-close return-65.7%five-year window

FY2025 revenue$0.26BIOVANCE BIOTHERAPEUTICS, INC.

Net margin-148.4%FY2025

P/E snapshot-27.9xone ratio, not a verdict

Prism attention10.9%share across these five

Filing track recordRevenue, USD billions

+22061.6%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1388.7%

52-week position82% through range

$1.76$9.36

News mentions1.2K

Community mentions0partial coverage

U.S.-scope patents897

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal74/100
Management stability90/100
Market position0/100
Capital-event signal59/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2GLUE · Nasdaq

Monte Rosa Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2020Cambridge, Massachusetts$1.14B market cap

View full Companies Radar profile

50Moderate

Snapshot price$13.38as of page date

Monthly-close return-59.9%five-year window

FY2025 revenue$0.12BMonte Rosa Therapeutics, Inc.

Net margin-31.2%FY2025

P/E snapshot-7.1xone ratio, not a verdict

Prism attention4.5%share across these five

Filing track recordRevenue, USD billions

+63.5%

FY2024–FY2025 · 2 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 63.5%

52-week position41% through range

$4.60$25.77

News mentions472

Community mentions5partial coverage

U.S.-scope patents46

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal69/100
Management stability90/100
Market position0/100
Capital-event signal71/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3BEAM · Nasdaq

Beam Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2017Cambridge, Massachusetts$3.03B market cap

View full Companies Radar profile

48Cautious

Snapshot price$29.32as of page date

Monthly-close return-72.5%five-year window

FY2025 revenue$0.14BBeam Therapeutics Inc.

Net margin-57.2%FY2025

P/E snapshot-6.2xone ratio, not a verdict

Prism attention14.2%share across these five

Filing track recordRevenue, USD billions

+169.5%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 28.1%

52-week position60% through range

$16.02$38.26

News mentions1.5K

Community mentions103partial coverage

U.S.-scope patents557

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal75/100
Management stability90/100
Market position5/100
Capital-event signal49/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4DNA · NYSE

Ginkgo Bioworks

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2011Boston, Massachusetts$468.7M market cap

View full Companies Radar profile

42Cautious

Snapshot price$6.96as of page date

Monthly-close return-98.2%five-year window

FY2025 revenue$0.17BGinkgo Bioworks Holdings, Inc.

Net margin-183.8%FY2025

P/E snapshot-2.4xone ratio, not a verdict

Prism attention52.8%share across these five

Filing track recordRevenue, USD billions

-45.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.2%

52-week position13% through range

$5.37$17.58

News mentions5.6K

Community mentions193partial coverage

U.S.-scope patents385

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position25/100
Capital-event signal75/100
Innovation pulse3/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 34 M&A involvements, 5 asset-acquisition events and 8 contract events.

Innovation activity

Prism records 3 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5RGNX · Nasdaq

Regenxbio

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2008Rockville, Maryland$637.7M market cap

View full Companies Radar profile

36Cautious

Snapshot price$9.66as of page date

Monthly-close return-71.0%five-year window

FY2025 revenue$0.17BREGENXBIO Inc.

Net margin-113.8%FY2025

P/E snapshot-3.2xone ratio, not a verdict

Prism attention17.6%share across these five

Filing track recordRevenue, USD billions

-63.8%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -22.4%

52-week position39% through range

$5.46$16.19

News mentions1.9K

Community mentions6partial coverage

U.S.-scope patents690

Prism InsightsWhat sits behind the readiness signal
Observed risk 7/100higher means more observed risk

Earnings signal21/100
Management stability90/100
Market position8/100
Capital-event signal74/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 4 M&A involvements, 0 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 2 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Monte Rosa Therapeutics

-59.9%

Iovance

-65.7%

Regenxbio

-71.0%

Beam Therapeutics

-72.5%

Ginkgo Bioworks

-98.2%

Latest revenue

USD billions, official filing scope shown on each company card.

Iovance

$0.26B

Ginkgo Bioworks

$0.17B

Regenxbio

$0.17B

Beam Therapeutics

$0.14B

Monte Rosa Therapeutics

$0.12B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Monte Rosa Therapeutics

-31.2%

Beam Therapeutics

-57.2%

Regenxbio

-113.8%

Iovance

-148.4%

Ginkgo Bioworks

-183.8%

Prism news attention

Normalized share across these five names; attention is not quality.

Ginkgo Bioworks

52.8%

Regenxbio

17.6%

Beam Therapeutics

14.2%

Iovance

10.9%

Monte Rosa Therapeutics

4.5%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Ginkgo Bioworks leads the conversation

It holds 52.8% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.17B.

Price path

Monte Rosa Therapeutics leads the available price paths

Its monthly-close return is -59.9% for the five-year window. At the other end, Ginkgo Bioworks is -98.2% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Monte Rosa Therapeutics has the widest latest margin

Its FY2025 net margin is -31.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Iovance shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -27.9x while its five-year window price return is -65.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · IOVA

Iovance

1,153available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Leadership & governance

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+31.7%241 latest 12m vs 183 prior 12m

Machine-classified coverage tone

81.3% positive+1.5 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

immunotherapy 61tumor microenvironment 52cell-based therapies 20stock performance 16angiogenesis inhibitors 15cancer biomarkers 12car-t myeloma 8immunomodulatory drugs 7

Keyword tag occurrences in available Prism news records.

Coverage: 2013-09-26–2026-05-29 · trend and themes shown through 2026-05

Areas of research · BEAM

Beam Therapeutics

1,504available Prism news records

Prism top themes

Price action & investor response

Capital allocation & transactions

Earnings & financial performance

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+17.4%364 latest 12m vs 310 prior 12m

Machine-classified coverage tone

95.5% positive+4.8 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 119crispr-cas9 67crispr applications 63rare disease clinical trials 49stem cell banking 49gene delivery systems 32rare disease treatment 31cell-based therapies 27

Keyword tag occurrences in available Prism news records.

Coverage: 2018-05-07–2026-06-19 · trend and themes shown through 2026-06

Areas of research · DNA

Ginkgo Bioworks

5,592available Prism news records

Prism top themes

Price action & investor response

Leadership & governance

Earnings & financial performance

Capital allocation & transactions

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-9.6%637 latest 12m vs 705 prior 12m

Machine-classified coverage tone

81.4% positive-6.6 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

synthetic biology 81enzyme engineering 60reforestation 56native species preservation 55forest conservation 55biodiversity monitoring 54conservation status 54extinction prevention 54

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-19 · trend and themes shown through 2026-06

Areas of research · RGNX

Regenxbio

1,869available Prism news records

Prism top themes

Price action & investor response

Legal, arbitration & regulatory

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-3.2%394 latest 12m vs 407 prior 12m

Machine-classified coverage tone

78.4% positive-11.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 177rare disease clinical trials 66rare disease treatment 66stock performance 45orphan drug pricing 36orphan drug incentives 27gene delivery systems 23patent litigation 20

Keyword tag occurrences in available Prism news records.

Coverage: 2012-08-01–2026-06-02 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

BEAM

Beam Therapeutics

103 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 103 records remained after filtering.

DNA

Ginkgo Bioworks

193 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 193 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

IOVA

Iovance

through 2026-02-24

Earnings releases 19Lawsuits 3Company announcements 2Leadership changes 2Listing / IPO 2

2026-02-24
Earnings releases
On February 24, 2026, Iovance Biotherapeutics reported that 2025 was its first full calendar year of Amtagvi launch, delivering about 30% sequential fourth-quarter revenue growth to roughly $87 million and full-year product revenue of about $264 million, in line with guidance.
2025-08-29
Regulatory
Health Canada's conditional approval of Amtagvi for melanoma treatment
2025-05-31
Lawsuits
class action lawsuit was filed by investors who incurred losses exceeding $100,000.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GLUE

Monte Rosa Therapeutics

through 2025-05-27

Leadership changes 3Business contracts 2Earnings releases 1

2025-05-27
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monte Rosa Therapeutics $159.49 million 1.53 -$135.35 million $0.08 49.63 Aptose Biosciences N/A N/A -$51.21 million ($89.19) N/A
2025-02-14
Business contracts
Novartis has agreed to pay Monte Rosa $150 million up front, and the latter could bank as much as $2.1 billion in development, regulatory, and sales milestone rewards, beginning upon the start of phase II work, as well as tiered royalties on ex-U.S. net sales.
2024-05-30
Leadership changes
Phil Nickson, Ph.D., J.D., promoted to Chief Business and Legal Officer, joined the Company as General Counsel and has provided general legal support, including work on intellectual property matters and external business transactions.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BEAM

Beam Therapeutics

through 2025-10-28

Earnings releases 7Leadership changes 2M&A 2Regulatory 2Listing / IPO 1

2025-10-28
Earnings releases
This company is expected to post quarterly loss of $0.98 per share in its upcoming report, which represents a year-over-year change of +16.2%.
2025-10-08
Regulatory
Beam Therapeutics announced on Aug. 14 that the FDA granted regenerative medicine advanced therapy designation status for Beam-101.
2025-02-14
M&A
Beam adds targeting tech with $440M Guide buy

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

DNA

Ginkgo Bioworks

through 2026-02-19

Earnings releases 24Company announcements 4Business contracts 3Asset acquisitions 2Lawsuits 2

2026-02-19
Company announcements
Ginkgo Bioworks Holdings, Inc. today announced that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, beginning at 4:30 p.m. ET.
2025-11-17
Leadership changes
He’ll take over for Patrick DePriest, who took off for Texas-based manufacturer Saronic Technologies about 10 months ago.
2025-11-07
Earnings releases
Ginkgo Bioworks reported a loss of $1.45 per share versus estimates for a loss of $1.24 per share and a loss of $1.08 per share in the same period last year, representing a 34.26% increase in losses year over year.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RGNX

Regenxbio

through 2026-04-14

Earnings releases 13Leadership changes 13Lawsuits 2Listing / IPO 2Business contracts 1

2026-04-14
Lawsuits
According to the complaint filed in the U.S. District Court for the District of Maryland the plaintiff alleges on behalf of purchasers of REGENXBIO Inc. common shares between February 9, 2022 and January 27, 2026, that the defendants violated Federal Securities Laws.
2025-05-19
Business contracts
Regenxbio (RGNX) announced the closure of a non-dilutive, limited recourse royalty bond agreement of up to $250M with Healthcare Royalty.
2025-03-13
Earnings releases
ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576psychedelic mental health studies 1,328cannabis policy reform discussions 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 16–23. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Iovance leads the readiness ranking

Its Prism readiness score is 50/100, the highest in this five-company comparison.

Open Iovance in Companies Radar

Scale and margin leadership sit with Iovance and Monte Rosa Therapeutics

Iovance has the largest displayed latest revenue at $0.26B; Monte Rosa Therapeutics has the widest displayed latest margin at -31.2%.

Open Iovance in Companies Radar Open Monte Rosa Therapeutics in Companies Radar

Comparisons

Strongest versus weakest available price path

Monte Rosa Therapeutics is -59.9% for its five-year window; Ginkgo Bioworks is -98.2% for its five-year window.

Open Monte Rosa Therapeutics in Companies Radar Open Ginkgo Bioworks in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.26B for Iovance to $0.12B for Monte Rosa Therapeutics. Entity and filing-period labels remain visible on the company cards.

Open Iovance in Companies Radar Open Monte Rosa Therapeutics in Companies Radar

Anomalies

Ginkgo Bioworks has the widest attention-readiness rank gap

It ranks #1 by measured news attention (52.8%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Ginkgo Bioworks in Companies Radar

Iovance shows a price-operating divergence to inspect

Its displayed filing-revenue change is +22061.6% while its available monthly-close return is -65.7%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Iovance in Companies Radar

Explanations

Attention measures coverage volume, not quality

Ginkgo Bioworks's 52.8% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Ginkgo Bioworks in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Iovance's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 50/100 score.

Open Iovance in Companies Radar

Stress-test the largest divergence before forming a view

Compare Iovance's profile with Monte Rosa Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Iovance in Companies Radar Open Monte Rosa Therapeutics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.